It would be of great interest, therefore, to develop a non-viral gene delivery system that can mediate prolonged reporter gene expression in an animal tumour model. An effective way to achieve this goal is to use a plasmid DNA expression system which can be maintained as a functional, once it has been delivered to cells of the tumour model and provide them with good detectable levels of marker gene expression throughout their lifetime. Previous in vivo studies involving pDNA vectors have shown that viral promoters, such as the cytomegalovirus promoter is able to provide the highest levels of transgene expression initially but is followed with a subsequent decline in expression within two months. This decline in expression is promoterdependent and likely to be the result of transcriptional silencing of the promoter. Indeed, CpG methylation of the CMV promoter in various plasmid vectors has been found to have a negative effect on transgene expression both in vitro and in vivo. Recently, we and others have shown that a pDNA Temozolomide vector comprising a combination of a mammalian, tissue-specific promoter with a nuclear scaffold/matrix attachment region element can promote long-term episomal expression in vitro and in vivo. The S/MAR element provides a specific association of the vector with the nuclear matrix via scaffold attachment factor-A, tethering the vector to the chromosome scaffold during mitosis and bringing the plasmid into close contact with the cell’s replication machinery, therefore creating mitotic stability and maintaining the plasmid as an epigenetic entity through hundreds of cell divisions. The S/MAR element has been shown to have a protective effect on methylation-sensitive sites in the antitrypsin liver-specific promoter, but has no such effect on the CMV promoter, highlighting that a mammalian rather than a viral promoter is more suitable for long-term transgene expression with this vector. An S/MAR-containing plasmid has been developed for application to the liver by the utilisation of a liver-specific promoter, AAT, and has been shown to persist and express the luciferase transgene episomally over 6 months in hepatocytes. Given the long-term expression of these episomally maintained plasmids, an S/MAR based vector in combination with a mammalian promoter would appear to be ideal for use as a genetic marker of tumour cells. Plasmids containing an S/MAR sequence and a CMV promoter have previously been successfully transfected into CHO, HaCat, HeLa, K562 leukaemia cells, U251 glioma and primary fibroblast and have been shown to replicate and to be maintained as extra-chromosomal episomes. The work described here shows, for the first time, the use of an episomally maintained, pUbC-S/MAR plasmid, mediating persistent luciferase transgene expression to generate genetically labelled tumour cell lines which give rise to different cancers when applied in vivo. The cell lines used are a human hepatocellular carcinoma cell-line Huh7, which is derived from a patient with hepatocellular carcinoma and a human pancreatic carcinoma cellline, MIA-PaCa2. This work represents the development of murine tumour models derived from two different cell lines. Significantly, this study shows for the first time the establishment of genetically marked murine models of pancreatic and hepatocellular carcinomas using a non-viral episomal plasmid vector.